Participating in the development of:
The group of companies, comprising Holding “Generium” have been actively involved in the implementation of the “Pharma Strategy 2020”, the special program for the strategic development of pharmaceutical industry established by the Government of Russian Federation.
In 2009 JSC “Generium” has launched a large-scale manufacturing of Somatropin (Rastan®) and Coagulation Factor VII (Coagyl®-VII) in Russia. These medical products are included in the list of vital and essential pharmaceuticals (VEP) for Russian Federation.
The year of 2011 was marked with another milestone for JSC “Generium”, when we successfully launched a production of recombinant interferon beta-1b (Infibeta®), which is also included in the list of vital and essential pharmaceuticals (VEP).
In 2011 our Holding has successfully tendered for the contracts with the Ministry of Industry and Trade of the Russian Federation. As a result of this competition, the LLC IBC Generium has won the following State contracts:
- development and organization of the production of the medication imiglucerase (included in the list of VEP);
- transfer of innovative medicines based on the humanized monoclonal antibody against a vascular endothelial growth factor for the treatment of solid tumours and vascular diseases of the retina.